Skip to content

Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients.

Pilot Study of Banana Leaves as a Primary Wound Dressing for Partial Thickness Burn Wounds

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07453732
Enrollment
30
Registered
2026-03-06
Start date
2026-04-01
Completion date
2027-04-30
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Partial-thickness Burn, Pain, Second Degree Burn

Brief summary

This study plans to look at the benefits of banana leaves as a primary burn wound dressing. Study patients will be compared to historical patients

Detailed description

Historically, banana leaves have been used as a burn wound dressing in developing countries. Current literature on banana leaf dressings is limited to predominantly pediatric patients and surgical wounds (i.e. skin graft donor sites). The comparison dressing is often other non-standard burn dressings (e.g. boiled potato peel bandage) and these studies are almost exclusively performed in tropical locations where banana plants grow naturally (Africa and Asia). To date, no study on the effectiveness of banana leaf dressings has been done in the United States, nor has there been a focus on their effectiveness in second degree partial thickness burns. Our pilot study aims to establish the feasibility of using banana leaf dressings for second degree partial thickness burn wounds in adult patients, in a geographic location that does not support natural banana agriculture.

Interventions

Sterilized banana leaf as a primary non-adherent burn dressing

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* \<10% Total body surface area (TBSA) partial thickness burns * Patients age 18 to 99 * Primary admission (inpatient) to the UCHealth Burn and Frostbite Center * Burns \<48 hours old on admission

Exclusion criteria

* Patients \<18 years * Patients who are pregnant, incarcerated, or cognitively impaired * Burns \>48 hours old on admission * Patients with concurrent traumatic injuries * Patients with chemical, electrical, or friction burns * Full thickness burns * Burns to sensitive areas: face, genitals, hands, feet * Burns with evidence of infection on admission * Patients with a known allergy to bananas or latex * Patients with opioid use disorder or methamphetamine use disorder

Design outcomes

Primary

MeasureTime frameDescription
Pain scores, as measured using Number Pain Rating ScaleBefore, during and after each wound care session during hospitalization, approximately 14 daysThe Numeric Pain Rating Scale is a unidimensional subjective measure of pain intensity in adults, consisting of a scale from 0 to 10, where 0 represents "no pain" and 10 represents "worst pain imaginable" (or "worst possible pain").

Secondary

MeasureTime frameDescription
Total use of opioids and benzodiazepines during wound care sessionsDuring hospitalization, approximately 14 daysTotal morphine-milligram equivalent (MME) and milligrams of benzodiazepines used during each wound care session
Time to wound closureDuring hospitalization or at follow-up in clinic, approximately within 1 monthClinical determination of burn wound closure to be made by study team
Skin graft rateDuring hospitalization, approximately 14 daysPercentage of patients requiring skin grafting
Burn wound infection rateDuring hospitalization, approximately 14 daysPercentage of patients who develop burn wound infection as defined by the American Burn Association
Number of participants with at least one adverse eventEnd of study (1 year)Adverse events will only include those that are determined to be related to study device.

Countries

United States

Contacts

CONTACTCameron Gibson, MD
cameron.2.gibson@cuanschutz.edu720-848-3251
PRINCIPAL_INVESTIGATORCameron Gibson, MD

University of Colorado, Denver

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026